The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

The menopausal transition may represent an inflection point for worsening of multiple sclerosis in women, according to study findings.

MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...

If you get out and about in Little Rock, chances are you've seen Sarah Thomas' smiling face, been cheered by her vivacity.

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...

Patients should stop taking glatiramer acetate and seek immediate medical attention by going to an emergency room or calling ...

The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include ...

According to the National Cancer Institute, approximately 40.5% of Americans will be diagnosed with cancer at some point ...

And if you know her whole story, you may be marveling at the fact that she does all she does despite living with multiple sclerosis (MS) -- a disease that, as described on the National Multiple ...

Relapsing-remitting multiple sclerosis is a type of multiple sclerosis ... Some of these medications can have side effects. A doctor typically works with you to select a therapy that takes into ...

Doctors may recommend oral or infused steroid therapy for severe multiple sclerosis flare-ups that impact your functioning. Treatment with steroids can cause side effects. If you have multiple ...

Intranasal foralumab can modulate a number of immune cell types in people with non-active SPMS, developer Tiziana Life ...